Insider Selling: Beigene, Ltd. (NASDAQ:ONC) CEO Sells 58,590 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 58,590 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $249.13, for a total value of $14,596,526.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

John Oyler also recently made the following trade(s):

• On Monday, March 3rd, John Oyler sold 101,000 shares of Beigene stock. The shares were sold at an average price of $244.30, for a total transaction of $24,674,300.00.

Beigene Stock Performance

Shares of NASDAQ ONC opened at $247.07 on Monday. The firm has a market capitalization of $24.18 billion, a P/E ratio of -29.98, a PEG ratio of 7.73 and a beta of 0.65. Beigene, Ltd. has a one year low of $126.97 and a one year high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.

Beigene (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Analysts predict that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ONC shares. Macquarie raised their price target on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.